Zogenix

Modis Therapeutics, Inc. is a biopharmaceutical company focused on developing disease-modifying therapies for rare genetic diseases characterized by high unmet medical needs. Incorporated in 2016 and based in Oakland, California, the company is known for its lead therapy, MT1621, which aims to restore mitochondrial DNA replication fidelity. This therapy specifically targets thymidine kinase 2 deficiency (TK2d), an inherited mitochondrial disorder. By improving nucleotide balance and increasing mitochondrial DNA copy number, Modis Therapeutics' approach seeks to enhance cellular function and prolong the lives of affected patients. As of September 2019, Modis Therapeutics operates as a subsidiary of Zogenix, Inc.

Brabant Pharma is a pharmaceutical company focused on developing an oral treatment known as Brabafen for children suffering from Dravet Syndrome, a severe form of epilepsy characterized by frequent and catastrophic seizures. This condition often leads to significant mental and cognitive impairments, with a concerning mortality rate of 10%-15% among affected children. Standard anticonvulsant medications are typically ineffective for these patients, highlighting the critical need for effective alternatives. Brabafen, which is a low-dose formulation of fenfluramine, has shown exceptional efficacy based on extensive clinical data derived from up to 20 years of case studies. Due to the rarity of Dravet Syndrome, this treatment qualifies as an Orphan Product in both Europe and the United States, granting it data exclusivity for 10 and 7 years, respectively. Brabant Pharma aims to address the unmet medical needs of this vulnerable patient population through its innovative therapeutic approach.